GIT1 and triple-negative breast carcinoma: Furthermore, when we interrogated data from a publicly available cohort of triple negative breast cancer patients (n=67)12, we found that patients with GIT1 expression below the median had significantly poorer prognosis regarding event-free interval than those with GIT1 levels above the median (P=0.0411, hazard ratio = 1.625;Figure 3E).